Notes - Significant Accounting Policies For Preparation Of Consolidated Financial Statements
| Concept |
As at 2019-03-31 |
2018-04-01 to 2019-03-31 |
|---|---|---|
| Notes - Significant accounting policies for preparation of consolidated financial statements | ||
| Notes - Significant accounting policies for preparation of consolidated financial statements | ||
| Disclosure of scope of consolidation | ||
| Number of consolidated subsidiaries and names of major consolidated subsidiaries | — |
連結子会社の数 3社 連結子会社の名称 Laboratoires OncoTherapy Science France S.A.R.L. イムナス・ファーマ株式会社 株式会社Cancer Precision Medicine |
| Number of consolidated subsidiaries |
3
xbrli:pure
|
— |
| Disclosure about fiscal years, etc. of consolidated subsidiaries | — |
２．連結子会社の事業年度等に関する事項 連結子会社の決算日は連結決算日と一致しております。 |